Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Open Fracture
Interventions: 0.9% Sodium Chloride; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Blood Loss
Interventions: Intravenous Placebo, Intravenous Tranexamic Acid; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Postoperative Pain
Interventions: Acetaminophen, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postoperative Pain, Pregnancy, Obesity
Interventions: 0.9% Normal Saline, 0.2% Ropivacaine, 0.5% Ropivacaine, 0.75% Ropivacaine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Appetite Regulation, Obesity
Interventions: Exendin-(9-39) Acetate, Saline 0.9%; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 29 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Orbital Edema, Orbital Ecchymosis
Interventions: Tranexamic acid injection, Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML), normal saline - injection, normal saline - intravenous; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Respiratory Failure
Interventions: Hypertonic saline (3%), Placebo (0.9% saline); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rotator Cuff Tear
Interventions: 0.5% bupivacaine, Normal Saline; Drug
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years to 90 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Coronary Disease, Heart Diseases, Cardiovascular Diseases, Neurologic Manifestations
Interventions: Magnesium, 0.9% saline; Drug
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Surgery, Infection
Interventions: Polymyxin B in Normal Saline, Placebo: Normal Saline; Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 88 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Oral Mucositis
Interventions: ALD518, 0.9% saline; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more

Conditions: Post-ligation Cardiac Syndrome
Interventions: Milrinone infusion, Placebo infusion; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 3 Months
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Birmingham, Alabama • Orange, California • Palo Alto, California + 16 more

Conditions: Hypertension
Interventions: Sodium Butyrate 5 mmol, Sodium Butyrate 80 mmol; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Cardiovascular Disease
Interventions: FEIBA, Normal Saline; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Schwannomatosis, Schwannomas, Pain, Chronic
Interventions: Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo; Biological
Lead sponsor: Kara Chew; Other
Eligibility: 40 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Antibiotic Prophylaxis Surgery
Interventions: CeFAZolin 1000 MG, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: NTLA-2001, Placebo; Biological · Drug
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 39
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Escherichia Infection
Interventions: B7A (ETEC challenge strain), CssBA, dmLT, Placebo; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: IUD Insertion Pain, IUD Insertion
Interventions: Benzocaine 20%, Lidocaine 2%, Sham injection, Saline 0.9%; Drug · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault
Interventions: Dexamethasone, Normal saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Alzheimer Disease
Interventions: MK 6240; Drug
Lead sponsor: Tammie L. S. Benzinger, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Burn
Interventions: Instilled 1% Lidocaine, Placebo (0.9% Normal Saline); Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pain, Postoperative, Pain, Acute, Pain, Chest, Pain, Satisfaction, Patient, Opioid Use, Unspecified, Opioids; Harmful Use
Interventions: 0.25% Bupivacaine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Volume Reduction for Open Fracture Irrigation

Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty

Intravenous Acetaminophen in Craniotomy

Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

The Role of GLP-1 in Satiety Perception in Humans

The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery

Nebulized Hypertonic Saline for Mechanically Ventilated Children

Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion

Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery

Antibiotic Irrigation for Pancreatoduodenectomy

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Gut Butyrate and Blood Pressure in African Americans

FEIBA and Use of Blood Products in Cardiac Surgery

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

Intrauterine Device Insertion Pain Management

Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes

Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement